Cancer- and Chemotherapy-Induced Anemia

Rodgers, George M.; Becker, Pamela S.; Blinder, Morey A.; Cella, David; Chanan‐Khan, Asher; Cleeland, Charles S.; Coccia, Peter F.; Djulbegoviĉ, Benjamin; Gilreath, Jeffrey A.; Kraut, Eric H.; Matulonis, Ursula A.; Millenson, Michael; Reinke, Denise K.; Rosenthal, Joseph; Schwartz, Rowena; Soff, Gerald A.; Stein, Richard S.; Vlahović, Gordana; Weir, Alva B.

doi:10.6004/jnccn.2012.0064

Cited by 177 publications

(191 citation statements)

References 80 publications

(100 reference statements)

Supporting

Mentioning

173

Contrasting

Unclassified

Order By: Relevance

“…Anemia may develop either by impaired function in red blood cell (RBC) production or because of renal tubular damage following treatment with cytotoxic drugs as a consequence of chemotherapy in patients with breast cancer (4). Moreover, reduced levels of erythropoietin negatively affects RBC production in bone marrow, inducing anemia; accordingly, cancer patients with anemia have been shown to present abnormal erythropoietin levels (5).…”

Section: Introductionmentioning

confidence: 99%

Frequency of Chemotherapy Induced Anemia in Breast Cancer Patients

et al. 2016

View full text Add to dashboard Cite

Background: Breast cancer is the second most common malignancy in women, worldwide. Several etiologic factors may cause anemia in a patient with breast cancer. Anemia is a prevalent complication in patients with breast cancer who undergo chemotherapy which affects the health status and quality of life in these patients. The aim of this study was to evaluate the prevalence of anemia in patients with non-metastatic breast cancer who underwent adjuvant chemotherapy. Methods: In this cross-sectional study, 144 women with non-metastatic breast cancer who referred to radiotherapy and oncology department of Imam Reza hospital and met inclusion criteria were included. Data were obtained from patients' archived documents and were analyzed by SPSS software (version16). Results: In this study, 41% of patients were anemic before the chemotherapy and 43.1% of patients became anemic during and after treatment. The prevalence of post-chemotherapy anemia was significantly higher in advanced stages of cancer (P = 0.01). The chance of developing anemia were more in patients who underwent 8 cycles and AC + paclitaxel regimen, compared to the ones with 6 cycles and other regimens. There was no significant relationship between the prevalence of anemia and type of chemotherapy regimen, number of chemotherapy cycles, positive lymph nodes, co-morbidities, menstrual status, and body mass index (BMI). Conclusions: Due to the high prevalence of chemotherapy-induced anemia and its effects on quality of life, even mild degrees of anemia should be detected and evaluated before treatment. Considering early interventions is of cardinal importance, especially in the elderly.

show abstract

Section: Introductionmentioning

confidence: 99%

Frequency of Chemotherapy Induced Anemia in Breast Cancer Patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…However, Hb increments from baseline were moderately higher with the 2 FDA-approved regimens-weekly EA 40,000 U, and every 3 week DA 500 mcg-than with the extended dosing regimen. While the Hb response was fastest with the weekly EA regimen, it is unclear whether rapid Hb increment is beneficial, and subsequent to this study's completion the package inserts for both EA and DA were altered to recommend dose reduction or treatment cessation in patients with rapid Hb increment because of concerns about the potential for increased risk of thrombosis [8]. Other label changes included recommendation not to exceed a Hb of 12 g/ dL, and although the label had not yet been revised at the time this protocol was initiated, the treatment guidelines in this study protocol were consistent with that recommendation.…”

Section: Discussionmentioning

confidence: 99%

A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy‐associated anemia

et al. 2015

View full text Add to dashboard Cite

Erythropoiesis‐stimulating agents (ESAs) epoetin alfa (EA) and darbepoetin alfa (DA) increase hemoglobin (Hb) levels and reduce red blood cell (RBC) transfusion requirements in patients with cancer chemotherapy‐associated anemia (CAA). Extended‐interval ESA dosing (administration less than once weekly) is common with DA, but previous studies suggested that EA might also be administered less often than weekly. In this multicenter prospective trial, 239 CAA patients with Hb <10.5 g/dL were randomized to receive EA 40,000 U subcutaneously once weekly (“40K” arm), EA 80,000 U every 3 weeks (“80K”), EA 120,000 U every 3 weeks (“120K” arm), or DA 500 mcg every 3 weeks (“DA”), for 15 weeks. The primary endpoint was the proportion of patients achieving Hb ≥ 11.5 g/dL or increment of Hb > 2.0 g/dL from baseline without transfusion. Secondary endpoints included transfusion requirements, adverse events (AEs), and patient‐reported outcomes (PROs). There were no significant differences between treatment arms in the proportion of patients achieving Hb response (68.9% for 40K, 61.7% for 80K, 65.5% for 120K, and 66.7% for DA; P > 0.41 for all comparisons) or requiring RBC transfusion, but the median Hb increment from baseline was higher in the 40K and DA arms compared to the two extended dosing EA arms, and Hb response was achieved soonest in the weekly EA arm. There were no differences in PROs or AEs. The FDA‐approved schedules tested—weekly EA 40,000 U, and every 3 week DA 500 mcg—are reasonable standards for CAA therapy. Am. J. Hematol. 90:877–881, 2015. © 2015 Wiley Periodicals, Inc.

show abstract

“…Meanwhile, paclitaxel carboplatin regimen intake for 6 cycles in cervical cancer patients would cause Grade 3 anemia with the percentage of 48.3% [20]. Not to mention, a research by El-Deen et al also showed that 6 of 50 ovarium cancer patients who took paclitaxel carboplatin regimen suffered from severe anemia and 32 patients suffered from mild anemia [21].…”

Section: Difference In Blood Function Toxicitymentioning

confidence: 99%

Difference in Blood Function Toxicity Between Stadium Iib-Iiib Squamous Cell Cervical Cancer Patients With Paclitaxel Cisplatin and Paclitaxel Carboplatin Chemotherapy at Sanglah Hospital, Denpasar.

Indrayathi

Noviyani

Niruri

et al. 2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Paclitaxel cisplatin and paclitaxel carboplatin were chemotherapy regimens used for cervical cancer treatments at Sanglah Hospital, Denpasar. They came with hematologic toxicity side effects. This could be monitored from hemoglobin, thrombocyte, and leukocyte parameter. Data that compared the toxicity of these two regimens were still limited at Sanglah Hospital, Denpasar. Therefore, it was necessary to conduct a research about the difference in blood function toxicity between patients who underwent paclitaxel cisplatin chemotherapy and those who underwent paclitaxel carboplatin chemotherapy based on those three parameters.Methods: This was a prospective observational research with consecutive sampling, inclusion, and exclusion criteria. It was carried out from January to August 2016 at Sanglah Hospital, Denpasar. Patients were categorized into two groups based on their chemotherapy regimens. Next, blood samples from both groups were tested for its hemoglobin, thrombocyte, and leukocyte level before and after chemotherapy. The data underwent normality test using either Shapiro-Wilk or Mann-Whitney test with SPSS.Results: There were 17 patients who fulfilled the inclusion criteria. The result showed a decrease in hemoglobin, thrombocyte, as well as leukocyte values in patients who underwent paclitaxel cisplatin and paclitaxel carboplatin chemotherapy. Conclusion:The decrease of both hemoglobin and leukocyte level was not meaningful in both groups (p>0.05). Meanwhile, the decrease of thrombocyte level was meaningful in both groups (*p<0.05) in which patients who belong to paclitaxel carboplatin chemotherapy group showed a higher decrease of thrombocyte values.

show abstract

Cancer- and Chemotherapy-Induced Anemia

Cited by 177 publications

References 80 publications

Frequency of Chemotherapy Induced Anemia in Breast Cancer Patients

Frequency of Chemotherapy Induced Anemia in Breast Cancer Patients

A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy‐associated anemia

Difference in Blood Function Toxicity Between Stadium Iib-Iiib Squamous Cell Cervical Cancer Patients With Paclitaxel Cisplatin and Paclitaxel Carboplatin Chemotherapy at Sanglah Hospital, Denpasar.

Contact Info

Product

Resources

About